Other substances

Tetracycline

A polyketide antibiotic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Tetracycline is a polyketide antibiotic produced by Streptomycetes. Its bacteriostatic effect is a result of bacterial translation on ribosomes. Tetracycline might also disrupt bacterial cytoplasmic membrane (DrugBank).

Tetracycline on PubChem
Tetracycline on Wikipedia

Marketed as

ACHROMYCIN; ACHROMYCIN V; LIQUAMYCIN; TETRACYCLINE HYDROCHLORIDE

C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials	in silico	3.31		Aug/05/2020
Tetracycline as an inhibitor to the SARS‐CoV‐2 Spike protein Small molecule In silico	in silico	4.24	Predicted to bind SARS-CoV-2 Spike protein RBD.	Feb/22/2021

AI-suggested references

Link	Publication date
Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?	Jan/22/2022
Tetracycline as an inhibitor to the SARS-CoV-2	Feb/22/2021
Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations	Jul/09/2020
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study	Mar/25/2022
Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS-CoV-2 main protease and ACE2 protein.	Jul/06/2020
Prediction of repurposed drugs for treating lung injury in COVID-19.	Aug/26/2020
An ionophore breaks the multi-drug-resistance of Acinetobacter baumannii	Jul/06/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04716426	APT™ T3X on the COVID-19 Contamination Rate	Completed	Not Applicable	Jan/28/2021	Mar/25/2021
Alternative id - 4.485.847 Interventions - Drug: Tetracycline hydrochloride 3%\|Drug: Placebo Study type - Interventional Study results - Has Results Locations - Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - COVID-19 Contamination Rate.\|Number of Participants With Adverse Events\|Average Number of Adverse Events\|Days Over Which an Adverse Event Was Reported\|Other Virus or Bacteria Contamination Rate.

Export (.csv)